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Despite the global efforts, that have succeeded in reducing
tuberculosis (TB) mortality rate by 37% since 2000, TB was
one of the top 10 causes of death worldwide in 2016, the
main cause of deaths related to antimicrobial resistance and
the leading cause of death among people with HIV.1
According to WHO report, in 2016, there were an esti-
mated 10.4 million new TB cases worldwide, 10% of which
were people living with HIV. An estimated 1.7 million peo-
ple died from TB, including nearly 400,000 people who were
co-infected with HIV. This represents a decrease of 4% from
2015.1
Multidrug-resistant TB (MDR-TB) remains a public health
threat. WHO estimates that there were 490,000 MDR-TB
cases.1
Elimination of TB is not an easy goal. A realistic approach
to tuberculosis elimination2--5 has to rely on the development
of innovative diagnostic, treatment and preventive tools.
But it will not be possible without a strong political com-
mitment and addressing the socio-economic determinants
of the disease.6--12
The aim of this tuberculosis series is to present an update
on tuberculosis and provide a framework for future dis-
cussions among clinicians for the development of strategies
towards tuberculosis elimination.
Despite the evolution in tuberculosis diagnostic tools, we
still have several unmet needs -- we need diagnostic tests
which are more accurate, more rapid, affordable, simple
and with the ability to give a same-day result at point of
care. We will discuss the diagnostic methods available and
the potential impact of potential point of care diagnostics
for tuberculosis.13 We will then update on the role of the
newly developed drugs as well as repurposed drugs.14
There is a growing consensus on the need to act on the
social determinants and co-morbidities of tuberculosis. It
will not be enough to act only in diagnostics and treatment.
There is a need to identify interventions ensuring social pro-
tection and tackling the challenges of urbanization in order
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f disease.15
To provide proper treatment for MDR-TB cases may be
challenge due to the limited availability of second-line
rugs, occurrence of serious adverse events, risk of further
esistance.3,16--20 We will discuss the available tools to help
hysicians to manage these difﬁcult cases.21
Tuberculosis in children remains a partially neglected
opic, and this is why a speciﬁc article will present the
tate-of-the-art management of tuberculosis and latent
uberculosis infection in children.22
Given the migration crisis a speciﬁc article ‘making the
oint’ on the migrant and refugee emergency, and on the
ecessary response of national programmes in terms of pre-
ention, diagnosis and treatment has been included.23
Finally, given the difﬁculties of managing NTM we have
ncluded a special article on this difﬁcult topic.24
Overall, the path forward for the lowest TB burden
ountries seems clear: continue to improve surveillance
ithin coordinated national programmes; decrease diagno-
is and treatment delay; approach and manage vulnerable
opulations; promote effective treatment for active TB in
rder to prevent drug resistance; and increase the impact
f preventive actions -- screening for latent tuberculosis
nfection and treatment of those infected. This will not hap-
en without high-level political commitment and continuous
edical education of health staff.
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